Nguyen, Nina
Chaudhry, Sana http://orcid.org/0000-0003-1559-0974
Totiger, Tulasigeri M.
Diaz, Robert
Roberts, Evan
Montoya, Skye
Pardo, Gabriel
Pardo, Alejandro
Afaghani, Jumana
Affer, Maurizio
Jahn, Jacob
Bradley, Terrence
Maura, Francesco
Kazandjian, Dickran
Bilbao, Daniel
Chapman, Jennifer
Landgren, Ola
Hoffman, James
Taylor, Justin http://orcid.org/0000-0003-4407-6325
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K08CA230319)
American Society of Hematology
Article History
Received: 14 February 2022
Accepted: 29 September 2022
First Online: 19 October 2022
Competing interests
: T.B.: AbbVie: membership on an entity’s Board of Directors or advisory committees, speakers bureau; Novartis: consultancy, membership on an entity’s Board of Directors or advisory committees. F.M.: OncLive: honoraria; Medscape: consultancy, honoraria. D.K.: Arcellx: honoraria, membership on an entity’s Board of Directors or advisory committees; BMS: honoraria, membership on an entity’s Board of Directors or advisory committees. O.L.: adaptive: honoraria; binding site: honoraria; BMS: honoraria; Cellectis: honoraria; Amgen: honoraria; Janssen: honoraria; Celgene: research funding; Janssen: other: IDMC; Janssen: research funding; Takeda: other: IDMC; Amgen: research funding; GSK: honoraria. J.T.: Karyopharm: honoraria.